Wednesday, January 2, 2019

APRINOIA Therapeutics Licenses Tau PET Imaging Tracer APN-1607 to Celgene

TAIPEI, Taiwan, Jan. 2, 2019 /PRNewswire/ -- APRINOIA Therapeutics, a clinical-stage biotechnology company developing therapeutics and diagnostic imaging tools for neurodegenerative diseases announced today that it has entered into a non-exclusive licensing agreement with Celgene...



from PR Newswire: https://prn.to/2F5Es1Y

No comments:

Post a Comment